The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing hypocretin neurobiology and narcolepsy pharmacotherapy without original human trial data or systematic synthesis.
PubMed 16766052 · doi:10.1016/j.tips.2006.05.006
What was done
This narrative review summarizes the neurobiological understanding of hypocretins (orexins), their role in the pathophysiology of human narcolepsy, existing and newer therapeutic strategies, and future pharmacological targets based on the neuropeptide system.
What was found
The review notes that the primary pathophysiology of human narcolepsy is the loss of lateral hypothalamic neurons producing hypocretin, with approximately 90% of individuals with narcolepsy and cataplexy demonstrating hypocretin ligand deficiency. It describes standard treatments (amphetamine-like stimulants, antidepressants), newer agents (modafinil, sodium oxybate), cerebrospinal fluid hypocretin-1 diagnostic assays, and the prospective role of hypocretin receptor agonists. Specific numerical trial data or effect sizes for pharmacological treatments are not reported in the abstract.
Why it matters
It consolidates evidence linking hypocretin loss directly to the pathogenesis of narcolepsy with cataplexy, establishing a mechanistic rationale for hypocretin-based diagnostics and receptor agonist development.
Limits
The abstract describes a non-systematic narrative review with no primary empirical data or meta-analytic pooling. No study counts, sample sizes, or quantitative outcome metrics are reported in the abstract.
Cited by
- supports Seiji Nishino and Emmanuel Mignot discovered the genetic basis of narcolepsy in the orexin/hypocretin system.